110837-53-1

Basic information

• Product Name: 2-(2-chloroethoxy)-5-nitrobenzaldehyde
• Synonyms: 2-(2-chloroethoxy)-5-nitrobenzaldehyde
• CAS NO: 110837-53-1
• Molecular Formula: C₉H₈ClNO₄
• Molecular Weight: 229.61712
• EINECS: -0
• Mol File: 110837-53-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 395.9±32.0 °C(Predicted)
• Appearance: /
• Density: 1.393±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-(2-chloroethoxy)-5-nitrobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-chloroethoxy)-5-nitrobenzaldehyde(110837-53-1)
• EPA Substance Registry System: 2-(2-chloroethoxy)-5-nitrobenzaldehyde(110837-53-1)

Safety Data

• Hazardous Substances Data: 110837-53-1(Hazardous Substances Data)

Usage

General Description

2-(2-chloroethoxy)-5-nitrobenzaldehyde is a chemical compound with the molecular formula C9H8ClNO4. It is a yellowish crystalline solid with a molecular weight of 215.62 g/mol. 2-(2-chloroethoxy)-5-nitrobenzaldehyde is commonly used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and dyes. It is also utilized as a key intermediate in the production of organic compounds and is employed in the research and development of new materials and substances. 2-(2-chloroethoxy)-5-nitrobenzaldehyde may also have applications in the field of medicinal chemistry and drug discovery due to its unique chemical properties and reactivity.

Upstream product

• 2460-58-4 2-hydroxy-4-nitrobenzaldehyde 
• 107-06-2 1,2-dichloro-ethane 
• 97-51-8 5-Nitrosalicylaldehyde 
• 107-04-0 1-Bromo-2-chloroethane 

Downstream Products

• 937273-30-8 [2-(2-chloroethoxy)-5-nitrophenyl]methanol 
• 937273-31-9 1-(2-chloroethoxy)-2-((allyloxy)methyl)-4-nitrobenzene 
• 937273-32-0 1-(2-{4-nitro-2-[(prop-2-en-1-yloxy)methyl]phenoxy}ethyl)pyrrolidine 
• 1312603-46-5 4-(2-chloroethoxy)-3-((allyloxy)methyl)benzenamine 
• 937273-33-1 3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)phenylamine 
• 1312603-57-8 N-(4-(2-chloroethoxy)-3-((allyloxy)methyl)phenyl)-4-(3-((allyloxy)methyl)phenyl)pyrimidin-2-amine 
• 1312603-61-4 [4-(3-allyloxymethylphenyl)-5-methylpyrimidin-2-yl]-[ 3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)phenyl]amine 
• 1312603-62-5 [4-(3-allyloxymethylphenyl)-5-fluoropyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)phenyl]amine 
• 1312603-63-6 [4-(5-allyloxymethyl-2-methoxyphenyl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)phenyl]amine 
• 1312603-64-7 [4-(3-allyloxymethyl-5-fluorophenyl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)phenyl]amine 
• 1312603-65-8 [4-(3-allyloxymethyl-4-methoxyphenyl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)phenyl]amine 
• 1312603-66-9 [4-(3-allyloxymethyl-4-fluorophenyl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)phenyl]amine 
• 937271-58-4 allylmethyl-[2-(2-chloroethoxy)-5-nitrobenzyl]amine 
• 1354567-01-3 allylmethyl-[2-(2-ethylsulfanylethoxy)-5-nitrobenzyl]amine 

Relevant articles and documents

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is 50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK-HDAC pathway inhibiton achieved with a single molecule.

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7, 26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27) ,16,21,23-decaene (SB1518), a potent Janus Kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma

Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2 V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF). Herein, we describe the design and synthesis of a series of small molecule 4-aryl-2-aminopyrimidine macrocycles and their biological evaluation against the JAK family of kinase enzymes and FLT3. The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of 21c, a potent JAK2 (IC50 = 23 and 19 nM for JAK2 WT and JAK2V617F, respectively) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, respectively). Further profiling of 21c in preclinical species and mouse xenograft and allograft models is described. Compound 21c (SB1518) was selected as a development candidate and progressed into clinical trials where it is currently in phase 2 for MF and lymphoma.

PYRIDYL SUBSTITUTED PYRIMIDINE DERIVATIVES

The present invention relates to pyridyl substituted pyrimidine compounds that are useful as agents for the treatment of kinase related disorders such as proliferative disorders. More particularly, the present invention relates to oxygen linked and pyridy